North America BioSurgery Market

North America BioSurgery Market Size (2023 to 2028)

The size of the BioSurgery Market in North America was valued at USD 9.10 billion in 2023. This value is estimated to be growing at a CAGR of 8.24% to reach USD 13.52 billion by 2028 during the forecast period.

Biosurgery is an emerging field that utilizes biomaterials, therapeutic, and sophisticated device technologies to improve the health of patients that are under post-surgical care or in the area of orthopedics. Most biosurgery products work on the principle of facilitating homeostasis and tissue healing in surgery. Biosurgery products aid in the process of hard tissue regeneration in ortho-biologics as well. Recent developments include a bone graft implantation made up of polyetheretherketone and synthetic hydrogel technologies, a combination of bioactive products such as sealant and orthobiologics.

The primary driver of the North America Bio Surgery market is a rise in the sport and spine-related injuries. The increase in per capita healthcare expenditure, the increase in the number of surgeries due to the rise in the obese population along with lifestyle disorders are other factors bolstering the market growth.

Despite the numerous advantages, the market growth is still hampered by factors such as the high costs, and the growing preference of consumers for minimally invasive surgeries as opposed to the conventional one.

This research report on the North America BioSurgery Market has been segmented and sub-segmented into the following categories.

• By Type: Sealants, Haemostatic Agents, Adhesion Barriers, Soft Tissue Attachments, Bone Graft Substitutes, and Staple line Reinforcement Agents
• By Application: Orthopaedic, General, Neurological, Cardiovascular, Reconstructive, Gynaecological, Urological, and thoracic Surgeries.
• By Country: the United States, Canada, and the Rest of North America.

Regional Analysis

In 2019, North America accounted for the leading shares in the global Biosurgery market. The rising aging population, the increasing prevalence of chronic diseases, and related surgeries are the critical factors that increase the North American bio-surgery market's growth. 

United States Biosurgery market held the highest share in the North American market in 2019. Growth in the number of surgeries due to an increase in the obese population and lifestyle disorders is majorly driving the market growth. Increasing the adoption of advanced surgical tools and devices is anticipated to make tremendous growth opportunities for the North American market in the coming years. Increasing prevalence of chronic diseases such as cardiovascular disease rising demand of the market. According to the American Heart Association Research, cardiovascular disease valued around more than 840,678 deaths in the United States in 2018. Rising prevalence of heart disease and diabetes, increasing healthcare expenditure, and advancements in technology are other factors that drive the growth of the North America bio-surgery market. 

Canada is anticipated to be a lucrative region for the Biosurgery market. Improvements in healthcare services and reimbursement policies in this region are expected to aid regional growth. Other factors driving the market growth are the increase in per capita healthcare expenditure. The rise in the number of surgeries is the factor that increases the Canadian Biosurgery market's growth.

Companies leading the North American BioSurgery Market profiled in the report are Baxter International, C.R. Bard, Johnson & Johnson, Covidien PLC, Getinge Group, B. Braun Melsungen AG, Cryolife Inc., Stryker Corporation, Hemostasis LLC., and Sanofi Group.